US5162352A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs
Assignee: ER Squibb and Sons LLC
•
Filing: 1991-08-22
•
Granted: 1992-11-10
•
Expires: 2011-08-22
Abstract
Abstract 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs are provided which are thromboxane A 2 (TXA 2 ) receptor antagonists and have the structural formula ##STR1## wherein m is 1, 2 or 3, n is 1, 2, 3 or 4 and p is 2 to 18. These compounds are also useful in identifying thromboxane receptors in various tissue.
Inventors
- 👤 Steven E. Hall
- 👤 Martin L. Ogletree
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:19
CPC Classifications
C; C07; C07D; C07D519/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
30 words
A compound having the formula ##STR13## including all stereoisomers thereof, wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; and p is 2 to 18.
Claim 2
Dependent Claim
30 words
A compound having the formula ##STR13## including all stereoisomers thereof, wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; and p is 2 to 18.
Claim 3
Dependent Claim
19 words
The compound as defined in claim 1 wherein m is 1 or 2 and n is 2 or 3.
Claim 4
Dependent Claim
23 words
The compound as defined in claim 1 wherein m is 1 and n is 2 or 3 and p is 4 to 12.
Claim 5
Dependent Claim
11 words
The compound as defined in claim 1 having the formula ##STR14##
Claim 6
Dependent Claim
11 words
The compound as defined in claim 1 which is [1S-(1α,2α,3α,4α)[-2-[[3-[4-[[[8-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]octyl]amino]carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid.
Claim 7
Dependent Claim
31 words
A method of inhibiting platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
Claim 8
Dependent Claim
27 words
A composition for inhibiting platelet aggregation and bronchoconstriction comprising a therapeutically effective amount of a compound as defined in claim 1, and a pharmaceutically acceptable carrier therefor.
Claim 9
Dependent Claim
25 words
A method of inhibiting platelet aggregation which comprises administering to a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
Claim 10
Dependent Claim
27 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host a therapeutically effective amount of a compound as defined in claim 1.
Claim 11
Dependent Claim
31 words
A method for treating toxemia during pregnancy, which comprises admininstering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
Claim 12
Dependent Claim
32 words
A method for preventin or reducing venous thrombosis, which comprises administering to a mammalian host in need of such treatment a therapeutically effecitve amount of a compound as defined in claim 1.
Claim 13
Dependent Claim
35 words
A method for preventing or reducing platelet loss during extracorporeal circulation which comprises administering to a mammalian host in need of such treatment a therapeutically effective amount of a compound as defined in claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-10 | 1996-05-11 | 1996-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-10 | 2000-05-11 | 2000-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-10 | 2004-05-11 | 2004-11-10 | $7700.00 | Window Closed / Lapsed |